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Abstract 
Schwann cell development and peripheral nerve myelination require the serial 
expression of transcriptional activators, such as Sox10, Oct6/Scip/Pou3f1 and 
Egr2/Krox20. Here we show that transcriptional repression, mediated by the zinc-
finger protein Sip1, is essential for differentiation and myelination. Mice lacking Sip1, 
which is transiently expressed early in the Schwann cell lineage, develop a severe 
peripheral neuropathy, caused by the failure of axonal sorting and the virtual absence 
of myelin. Sip1-deficient Schwann cells continuously express repressors of lineage 
progression. Moreover, negative regulators of transcription, such as Sox2 and Hey2, 
emerge as direct Sip1 target genes, supporting a model of 'inhibition of inhibitors' in 
myelination control. When Sip1 is deleted in adult mice, Schwann cells readily 
dedifferentiate following peripheral nerve injury and become 'repair cells'. However, 
nerve regeneration and remyelination are both impaired, demonstrating that Sip1, 
although undetectable in adult Schwann cells, has a latent function throughout life.  
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Introduction 
The successive developmental stages of Schwann cell proliferation, axon sorting and 
myelination are regulated by a feed-forward cascade of transcriptional activators that 
ultimately up-regulate a large number of genes encoding myelination-associated 
enzymes and myelin structural proteins 1-3. Well studied examples include the 
transcription factor Krox20 (Egr2), as illustrated by Krox20 mutant Schwann cells, 
which successfully sort axons but fail to generate or maintain myelin membranes 4; 5. 
Also the transcription factors Oct6 and Sox10, developmentally upstream and directly 
interacting with Krox20 promote Schwann cell differentiation and myelination 6,7. 
Sox10 null mutant mice die prenatally with a lack of peripheral glia, revealing an early 
function of this transcription factor in the neural crest lineage, whereas later Schwann 
cell-specific Sox10 inactivation leads to developmental arrest at an immature stage 
8,9.  
 
Several transcription factors have also been identified as "negative regulators" of 
myelination, including both transcriptional activators (e.g. Sox2, c-jun, Pax3, Notch-
ICD) and inhibitors (Id2). While the most likely function of these factors is driving 
Schwann cell "de-differentiation" after injury and in preparation for nerve repair 
(Jessen and Mirsky, 2008), their presence interferes with myelination and myelin 
maintenance. This raises the question how inhibitory regulators themselves are 
controlled during Schwann cell differentiation. Transcriptional repressors are 
plausible candidates. For example, the co-repressor Nab (NGFI-A/Egr-binding) is 
essential for PNS myelination 10. However, when associated with Krox20 this protein 
is a co-activator of myelin protein genes, and the significance of gene repression by 
Nab/Krox20 complexes in Schwann cells is unclear 11,12. Also the zinc-finger protein 
Ying-Yang (YY1), an essential transcriptional inhibitor in myelinating 
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oligodendrocytes (He et al., 2007), acts as a transcriptional activator in the peripheral 
nervous system (PNS), immediately upstream of Krox20 (He et al., 2010).  
 
Smad-interacting protein-1 (Sip1, also known as Zeb2 or Zfhx1b) is a widely 
expressed zinc-finger homeobox protein, originally identified by its binding to Smad1 
13,14. During epithelial to mesenchymal transition, SIP1 represses the transcription of 
several genes for cell adhesion molecules, such as E-cadherin 15-17. In the central 
nervous system, newly born neurons express Sip1 to down-regulate signalling 
proteins that drive adjacent neurogenesis (Seuntjens et al., 2009). Sip1 also 
regulates oligodendrocyte differentiation, because mutant cells fail to fully mature and 
make myelin 18.  
 
Similar to the expression of Sox10 in the PNS, Sip1 is also detectable early in the 
neural crest lineage 19. In humans, mutations of SOX10 and SIP1 have been 
associated with the clinically related Waardenburg syndrome type 4 and Mowat-
Wilson syndrome, respectively 20. For neural crest cells, even direct interactions of 
SOX10 and SIP1 proteins have been proposed, but this is also difficult to reconcile 
with their respective roles as transcriptional activators and repressors 21. Sip1 is a 
canonical transcriptional repressor and in crest-derived immature Schwann cells a 
candidate to 'release the brake' on differentiation that might be imposed by the 
negative regulators, such as Sox2. 
 
Here, we show that Sip1 targets indeed inhibitors of Schwann cell differentiation. 
Mice lacking Sip1 specifically in this lineage show a complete arrest of Schwann cell 
maturation and exhibit a virtually amyelinated phenotype. However, Sip1-deficient 
Schwann cells survive in vivo and maintain axonal integrity. While Sip1 is not 
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required for adult myelin maintenance and axonal integrity, after injury Sip1-deficient 
Schwann cells fail to efficiently support nerve regeneration.  
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Results 
 
SIP1 is expressed at early stages of Schwann cell development and after acute 
nerve injury 
To explore SIP1 expression by Schwann cells, we immunostained paraffin sections 
of mouse sciatic nerves at different developmental stages. SIP1 was exclusively 
localized to cell nuclei. At E18.5, about 70% of Schwann cells were Sip1-positive. At 
age P10, only single cells could be immunostained, and at P25 virtually all Schwann 
cells were SIP1-negative (Fig. 1a).  
 
To study the Schwann cell-specific function of Sip1, we bred Sip1 floxed mice 22 to 
mice expressing Cre under control of the desert hedgehog promoter, leading to 
recombination in the Schwann cell lineage between embryonic days (E) 11 and 13.5 
9,23, when most cells are at the precursor stage 24. Loss of Sip1 protein was 
confirmed by the absence of immunostaining (Fig. 1a).  
 
To determine possible Sip1 re-expression in de-differentiating Schwan cells after 
acute sciatic nerve injury, we also stained paraffin sections of the distal segment at 
different time points after a nerve crush (Fig. 1b). Six hours after injury, about ten 
percent of Schwann cells were Sip1-positive (9.8±1.9%). A similar fraction could be 
stained after 24 hours (6.9±4.8%), but this number increased with a significant 
scatter between animals up to 50% (33.7±20.2%) after 3 days (Fig. 1b). However, on 
day 14 after crush, a time point when remyelination is at its peak, only a few percent 
of all Schwann cells still expressed SIP1 (3.5±1,4%). We never detected Sip1-
positive cells in the contralateral unharmed nerve (Fig. 1b) at any of the time points 
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analysed. We conclude that SIP1 expression is transient in peripheral nerves, 
preceding myelination in development and remyelination after acute nerve injury. 
 
Mice lacking Sip1 in Schwann cells display severe defects of axon sorting and 
myelination 
Conditional mutants (Dhh-Cre::Sip1flox/flox) were born at the expected Mendelian ratio 
and phenotypically distinguishable from littermate controls in the second postnatal 
week, when they had reduced body size and developed ataxia and hind limb 
weakness (Suppl. Video 1). The latter progressed with age but never led to 
complete hind limb paralysis. Surprisingly, when electrically stimulating the sciatic 
nerve of conditional mutants it was difficult to record any compound muscle action 
potential, unlike in controls, which suggests major conduction blocks (Fig. 1f). 
However, Sip1 conditional mutants had a normal life span, and we only occasionally 
observed unexplained premature deaths.  
 
To assess the developmental stage of Sip1-deficient Schwann cells in amyelinated 
nerves, we immunostained cross-sections from mutants and controls for Krox20 (also 
known as Egr2) and Sox2, as prototype positive and negative regulators, 
respectively. S100β was taken as a marker for both, immature and mature Schwann 
cells. While Schwann cells in control mice robustly expressed Krox20 and S100β and 
were negative for Sox2, only a few Sip1-deficient Schwann cells expressed Krox20 
and S100β but about 30 percent were positive for Sox2 (Fig.1 c-e).  
 
At P25, the sciatic nerves of mutant mice were thinner and more translucent than 
those of controls (Fig. 2a,b). Immunostaining of cross-sections for axonal β−tubulin 
(TuJ1) and myelin basic protein (MBP) revealed closely packed, amyelinated axons 
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in mutants but not in controls (Fig. 2c,d). Also by electron microscopy, Sip1-deficient 
mice lacked peripheral myelination and revealed abnormal axon bundles, with 
Schwann cells engulfing larger groups of axons that also greatly varied in diameter 
(Fig.2 e,f,g,h,i). Within these bundles, interdigitating Schwann cell processes could 
be observed, but the majority of axons remained closely packed, resembling axons 
associated with immature Schwann cells in embryonic nerves (Fig. 2i). Most 
Schwann cells even failed to establish the one-to-one relationship with axons. Here, 
we noticed that the basal lamina of Sip1-deficient Schwann cells was often thin, 
discontinuous, and not attached to the glial cell membrane, providing a plausible 
cause of failed axonal sorting (25). Many Schwann cells displayed also 'redundant 
basal lamina loops'  (Fig. 2g).  
 
At one year of age, peripheral axons had grown in diameter, but the overall pathology 
appeared unchanged (Fig. 2j-m). Compared to P25, the total Schwann cell number 
was unaltered in mutants and the percentage of BrdU-positive (proliferating) cells did 
not differ between mutants and controls, quantified at E18.5, P10 and P25 
(Suppl.Fig.1). This suggests, that Sip1-deficient Schwann cells exit the cell cycle 
normally and survive in the absence of myelination.  
 
At all time points studied (including 1 year of age) we found no evidence for axonal 
degeneration, except for rare axonal swellings (not shown). This suggests that Sip1-
deficient Schwann cells can support axon survival, at least under conditions of 
reduced electrical activity and energy consumption, which is strongly suggested by 
the finding of conduction blocks (see above). 
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Sip1-deficient Schwann cells continuously express negative regulators of 
differentiation 
To further define the stage at which Sip1-deficient Schwann cells arrest in 
development, we performed a transcriptome analysis of sciatic nerves at age P25. 
Steady-state levels of more than 700 mRNAs differed (at least 2 fold) in abundance 
between the two genotypes. The 20 top up- and down-regulated genes are shown in 
Fig. 3a. We confirmed a subset of differentially regulated genes by quantitative real-
time PCR, selecting promyelinating factors as well as negative regulators of 
myelination (note the logarithmic scale in Fig. 3b,c). As predicted from the phenotype 
of Sip1-conditional mutants and the histological analysis, genes encoding myelin 
proteins were down-regulated in mutants compared to controls (Fig. 3c). This was 
also the case for promyelinating factors of PNS myelination, such as Oct6/SCIP and 
Krox20/Egr2 (Fig. 3c). Importantly, Sip1-deficient Schwann cells revealed the 
persistent expression of transcripts that are normally down-regulated at this age, 
(Fig. 3b). This includes the negative regulators of Schwann cell differentiation (e.g. 
Sox2, c-jun, Id2) and markers defining immature Schwann cells (e.g. Brn2, Gfap). 
Sip1-deficient Schwann cells also expressed very low amounts of S100β, a well-
known marker of both immature and mature Schwann cells (Fig. 3c). In addition, we 
identified the Notch effector Hey2 as one of the most strongly (16.7±1.4-fold) 
upregulated genes in our data set (Fig. 3a,b), as confirmed by quantitative PCR. 
Also other components of the Notch signaling cascade were upregulated in our 
microarray analysis in mutants compared to controls, such as Notch1 (1.3-fold), Hes1 
(1.6-fold) and jagged1 (1.9-fold), arguing for persistently activated, inhibitory Notch 
signaling in Sip1-deficient Schwann cells. Confirmed by RT-PCR, we also found 
highly elevated (13.4±3.1-fold) expression of the endothelin receptor B (Ednrb) gene, 
encoding an efficient repressor of Schwann cell differentiation upon ligand binding 26. 
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Taken together, Sip1-deficient Schwann cells are arrested at an early developmental 
stage, with a very low expression of maturation factors and persistent (abnormal) 
expression of several negative regulators. 
 
Schwann cell Sip1 directly represses negative regulators of differentiation  
To test for a possible direct effect of Sip1 as a repressor of relevant target genes, we 
performed luciferase gene reporter assays using the S16 Schwann cell line. 
Promoter regions of murine Sox2, Hey2 and Ednrb, each containing putative Sip1 
binding sites  (CACCT, schematically depicted in Fig. 3e), were cloned into the 
pGL2-luciferase plasmid (Fig.!3d, e). Next, S16 cells were co-transfected with the 
resulting pGL2 fusion constructs and increasing amounts of a Sip1 expression 
plasmid in which the expression of Sip1 was under control of the CMV5 promoter 
(pCMV5-Sip1). In the analysis of the following luciferase assays, activity of lysates 
from S16 cells co-transfected with the pGL2-luc plasmid containing the respective 
promoter fragment and the empty pCMV5 plasmid was considered 100%. Co-
transfection with the Sip1 expression construct led to a significant dose-dependent 
downregulation of luciferase activity when compared to co-transfection with the 
empty pCMV5 plasmid  (Fig. 3d). This strongly suggests that the genes selected for 
proof-of-principle experiments are indeed direct targets of Sip1-mediated repression. 
 
Sip1-mediated repression of Ednrb and Hey2 is functionally relevant in 
Schwann cells in vivo. 
To determine whether Sip1-mediated 'inhibition of inhibitors' is also functionally 
relevant in vivo, we generated Sip1 double mutant mice, i.e. in combination with one 
of two negative regulators (Ednrb and Hey2) for which floxed mutants were available 
27,28. By crossbreeding, we obtained two genotypes (Dhh-Cre::Sip1flox/flox::Ednrbflox/flox 
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and Dhh-Cre::Sip1flox/flox::Hey2flox/flox), termed Sip1/Ednrb-KO and Sip1/Hey2-KO in 
the following.  While we could not assume to reach a phenotypical "rescue" with the 
loss of only one inhibitor, we searched for histological signs of improvement in these 
double-mutants. We therefore immunostained cross-sections of sciatic nerves for 
Krox20 (Fig. 1d). Indeed, the number of labelled Schwann cell nuclei (in Sip1fl/fl 
controls 36.7±2.9 per section) was strongly reduced in Sip1 single mutants (to 
6.0±0.4), but increased significantly both in Sip1/Ednrb-dcKO (to 19.9±4.3) and in 
Sip1/Hey2-dcKO (to 16.8±2.9) sciatic nerves (Fig. 4a,b).  
 
Also at the morphological level, axon-Schwann cell units appeared more matured in 
Sip1/Ednrb and in Sip1/Hey2 conditional double-mutants, at least when compared to 
the large and unsorted fiber bundles of Sip1 single mutants (Fig. 4c). Quantifying 
Remak-like (partially sorted) bundles with only 1-5 axons at age P25 (Fig. 4d), their 
number was higher in sciatic nerve cross sections of double mutants (Sip1/Ednrb: 
51.1±9.4; Sip1/Hey2: 58.4±8.7) than Sip1 single mutants (DhhCre::Sip1fl/fl: 27.5±6.1). 
Thus, already the lack of one negative regulator (downstream of Sip1) improves the 
ability of Sip1 mutant Schwann cells to initiate axon sorting.  
 
 
Sip1-deficient Schwann cells are unable to efficiently support nerve 
regeneration 
Since Schwann cells reexpressed Sip1 after an acute nerve injury (Fig.1c), we asked 
whether the induction of Schwann cell de-differentiation and peripheral nerve 
regeneration would be affected by the absence of Sip1. To this end we inactivated 
Sip1 in Schwann cells of adult mice, using a tamoxifen-inducible PLPCreERT2 driver 
line 29. Recombination was induced at 6-8 weeks of age and efficient CreERT2 
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expression was confirmed, using a reporter mouse that expresses tdTomato 30, on 
sciatic nerve cryostat sections (Suppl.Fig.2). 
 
When Plp-CreERT2::Sip1fl/fl  mice were analysed 12 weeks after the last tamoxifen 
injection, sciatic nerve morphology and myelin sheath thickness appeared unaltered 
(Suppl. Fig.3). We then performed sciatic nerve crushes in mice 4 weeks after the 
last tamoxifen (or vehicle) injection. Footprints on a walking track were used to 
monitor functional recovery. For histological analyses, animals were sacrificed 28 
and 56 days after sciatic nerve crush. In these experiments, mice from the three 
control groups functionally recovered as expected and as measured by the sciatic 
functional index (SFI). However, Plp-CreERT2::Sip1fl/fl mice remained severely 
impaired until the end of this study (56 days after crush, Fig. 5a).  
 
In physiological tests, carried out 52 days after sciatic nerve crush, Sip1-floxed 
control mice regained significant motor nerve conduction. We recorded a velocity 
(NCV) of about 18±2.9 m/s, which is about 70% of the NCV of an unharmed 
contralateral nerve (33±5.2 m/s), as determined in mice of either genotype.  
In contrast, Sip1 conditional mutants maintained severe axonal conduction problems 
that did not allow us to measure a NCV (Fig. 5b,c). Distal amplitudes (normal 
contralateral nerve: 29.8±10.1mV) were still reduced 52 days after crush injury in 
control mice (10.9±4.4 mV), but not even detectable in Plp-CreERT2::Sip1fl/fl  
mutants, indicating a regeneration failure with irreversible conduction blocks. 
 
Indeed, when we immunostained sciatic nerve cross sections for myelin (MBP) and 
axons (Tuj1), virtually all fibers showed remyelination in control mice (Fig.6a, top 
panel), whereas in nerves of tamoxifen-induced Plp-CreERT2::Sip1fl/fl mutants we 
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observed large amyelinated fibers 8 weeks after injury (Fig.6a, bottom panel). We 
also analysed remyelination by electron microscopy (Fig. 6b). At 28 days and 56 
days after crush injury mutants exhibited significantly fewer remyelinated axons (Fig. 
6c, upper panel). 
 
Interestingly, by g-ratio analysis axons remyelinated in mutant (Plp-CreERT2::Sip1fl/fl) 
mice had the same myelin sheath thickness we determined in controls (Suppl.Fig.4). 
Also 56 days after crush, we still observed remyelinating Schwann cells with fewer, 
non-compacted myelin loops (Fig. 6d).  Thus, given the timing of Sip1 re-expression 
after acute nerve trauma (Fig.1c), Sip1 is likely required for early regenerative 
events, such Schwann cell "de-differentiation" or myelin repair.  
 
Sip1-deficient Schwann cells do not fully redifferentiate after nerve injury 
To distinguish between alternative Sip1 functions after nerve injury, we studied 
sciatic nerves in tamoxifen-treated Plp-CreERT2::Sip1fl/fl mice 3 days after 
transection. At this time, there was no significant difference in the number of 
preserved myelin sheaths (1650±89 per section), when compared with vehicle-
treated controls (1785±287) 2.0mm distal to the transection site (Fig. 7a). 
 
Also steady-state mRNA levels of Schwann cell dedifferentiation markers (Jessen 
and Mirsky, 2008), such as c-jun, Sox2 and p75ntfR were expressed at comparable 
levels in the distal stump (Fig. 7b and data not shown), whereas myelination 
markers, such as Krox20 and Mpz, were downregulated in both, mutants and 
controls, when compared to the contralateral nerve (Fig. 6b). Taken together, the 
early steps of Schwann cell dedifferentiation are not perturbed by the lack of Sip1.   
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We next analysed at a functional level the regenerative axon outgrowth of crushed 
sciatic nerves in conditional Sip1 mutants and controls, using the "pinch test".  When 
tested 4 days after injury, deeply anaesthetized mice of all three control groups 
showed a clear muscle reaction to a pinch of the sciatic nerve applied with a pair of 
forceps distal to the original crush site (Fig. 7c). However, the distance at which a 
response could be elicited differed between genotypes, with all control groups 
showing more efficient axon outgrowth (e.g. 6.6±0.8 mm in mice lacking Cre) 
compared to tamoxifen-treated Sip1 mutants (5.4±1.3 mm).  
 
We hypothesized, that reduced regenerative capacity is caused by poor Schwann 
cell differentiation. We therefore analysed the distal stump of sciatic nerves at a late 
time point (56 days after crush), when control mice had fully recovered (Fig. 7d). 
Indeed, in Sip1 mutants we could still detect a significant expression of 
dedifferentiation markers, such as Sox2 and Id2 (Fig. 7d). Interestingly, Hey2 mRNA 
was only upregulated in mutant nerves, an "ectopic" expression similar to that found 
in Sip1-deficient Schwann cells at age P25. In contrast, Krox20 was downregulated 
in comparison to its expression in uninjured mutant nerves (Fig.7d). Taken together, 
Sip1-deficient Schwann cells can dedifferentiate after injury, but often fail to 
redifferentiate and provide myelin repair. 
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Discussion 
 
We have identified an essential regulator of Schwann cell differentiation and 
peripheral myelination, the two-handed zinc finger/homeodomain protein Sip1. In 
contrast to previously described promyelinating transcription factors in the Schwann 
cell lineage, such as Oct6, Krox20, or Sox10, which activate the transcription of 
down-stream factors and ultimately myelin-associated genes, Sip1 is a transcriptional 
repressor and more widely expressed (Verschueren et al., 1999).  
 
The developmental defect of conditional Sip1 mutant mice is also more severe than 
that of Oct6 or Krox20 mutants. Deletion of Oct6 causes only a transient arrest of 
Schwann cell differentiation after radial sorting, i.e. at the pro-myelin stage 
(Bermingham et al., 1996; Jaegle et al., 1996). Likewise, Schwann cells lacking 
Krox20 are able to sort axons but then completely fail to myelinate (Topilko et al., 
1994). Null mutant mice of Sox10, a gene already expressed in the emerging neural 
crest, die embryonically with a lack of all peripheral glia (Britsch et al., 2001). Only 
later cell-specific deletion of Sox10 after Schwann cell specification (induced by Dhh-
Cre as in Sip1 cKO) leads to a similar developmental arrest in peripheral nerves with 
the lack of radial axonal sorting and a virtual absence of myelin (Finzsch et al., 2010). 
Early arrest of Schwann cell maturation has also been observed in the context of 
chromatin remodelling. Mice in which Schwann cells lack Brg1, a subunit of the BAF 
chromatin-remodelling complex that is recruited by Sox10, develop a severe 
peripheral neuropathy and die prematurely (Weider et al., 2012). In comparison, Sip1 
conditional mutants survive much better, despite the same sorting defect and lack of 
myelination. We speculate that Schwann cell-mediated axonal support, which 
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protects from conduction blocks and lethal breathing defects is largely independent of 
Sip1.  
  
The hierarchical relationship of the known transcription factors in the Schwann cell 
lineage is complex, owing in part to their broad temporal expression domains and 
changing molecular interactions, including positive feedback loops (Stolt and 
Wegner, 2015). For example, Krox20 is activated in Schwann cell precursors by the 
positive regulators Oct6 and Sox10, which then collectively upregulate genes for 
myelin proteins and enzymes of the lipid biosynthesis pathway. How are these feed-
forward loops developmentally controlled? Our data on Sip1 suggest the existence of 
several brakes in the system, with the loss of Sip1 leading to continous expression of 
developmental inhibitors that block axonal sorting and myelination. This group of 
negative regulators is overlapping but not identical to other factors known to drive 
programmed de-differentiation of mature Schwann cells, such as c-Jun, after nerve 
injury (see below).  
 
Whereas the morphological defects of dysmyelination are strikingly similar in 
conditional Dhh-Cre::Sox10 and Dhh-Cre::Sip1 mutant mice, it is surprising that in 
Sip1-deficient mice all Schwann cells survive. Despite the virtual absence of myelin 
and similarly severe neuropathy, conditional Sip1 mutant mice have a normal life 
span, and Sip1-deficient Schwann cells support axon survival at least to some extent. 
We also note that in Sip1-deficient Schwann cells Sox10 mRNA itself is unaltered in 
abundance (data not shown).   The transcriptional (co-)activator Sox10 is expressed 
throughout the Schwann cell lineage and directly binds to Oct6 and Krox20, 
potentially affecting a broader set of myelin-associated genes (Ghislain and Charnay, 
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2006),  including most likely those that are required for survival and axonal metabolic 
support.  
 
By expression profiling of peripheral nerves from Sip1 mutant mice and by functional 
analysis of different promoter-reporter constructs we have identified several direct 
target genes of Sip1, which include known negative regulators of myelination and 
factors previously associated with Schwann cell de-differentiation. Thus, our findings 
suggests that negative regulatory proteins such as Sox2, Hey2, or Ednbr1 need to be 
down-regulated early in development in order for Schwann cell differentiation, axonal 
sorting and myelination to proceed (Fig. 8).  
 
We cannot formally exclude that also transcriptional activation of unknown target 
genes by Sip1 (e.g. in combination with unknown coactivators) promotes Schwann 
cell differentiation in wild-type mice. However, the most likely explanation why 
conditional Sip1 mutants display very low expression of Krox20 and other myelin 
protein genes is a secondary developmental arrest.   
 
Since Sip1 itself is only transiently expressed, the down-regulation of its target genes 
("inhibiting the inhibitors") most likely allows immature Schwann cells to overcome a 
developmental block, after which their further differentiation becomes Sip1-
independent. At least two genes appear to contribute to this block (Hey2 and Ednbr2) 
when studied along with Sip1 in corresponding double-mutant mice, whose 
developmental potential is significantly improved, as quantified by the number of 
Krox20 expressing Schwann cells. On the other hand, normally myelinated (adult 
wild-type) nerves, exhibit the absence of both Sip1 and its repressed target gene 
product(s), strongly suggesting that also factors other than Sip1 maintain the brake 
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on the expression of inhibitors and factors that would otherwise trigger de-
differentiation. The identity of these repressors is not known. Epigenetic silencing, 
which has been studied at early stages of CNS myelination (Hernandez and 
Casaccia, 2015) could also play a role.  
 
In our study, we identified Sip1 as a transcriptional repressor of Ednrb and Sox2, two 
known inhibitors of Schwann cell maturation, as well as of Hey2, a downstream 
effector of Notch signalling. We have selected these genes from a much larger group 
of abnormally up-regulated genes in order to show proof-of-principle for direct 
transcriptional repression by Sip1, as well as for their putative inhibitory function in 
Schwann cell differentiation. The latter was indeed possible in conditional double-
knockout mice. 
 
Two of these genes had been previously associated with the Schwann cell lineage. 
The endothelin B receptor (Ednrb) localizes to the plasma membrane of Schwann 
cell precursors and, upon binding of endothelin, delays the generation of mature 
Schwann cells, both in vitro and in vivo Indeed, Ednrb null mutant Schwann cells 
differentiate earlier than normal (Brennan et al., 2000; Stewart et al., 2001). 
  
Sox2 is also a member of the Sry-related HMG box familiy of transcription factors, 
but (unlike Sox10) widely expressed and well known for its role in generating 
pluripotency (Masui et al., 2007). Sox2 is down-regulated early in Schwann cell 
development, coinciding with Krox20 expression (Le et al., 2005a; Parkinson et al., 
2008).  Recently, it has been shown that overexpression of Sox2 (a transcriptional 
activator) leads to persistent proliferation of Schwann cells and inhibits myelination, 
! 19!
implicating Sox2 as a negative regulator of Schwann cell maturation in vivo (D. 
Parkinson, personal communication).  
 
Hey2 is a member of the hairy and enhancer-of-split related bHLH transcription factor 
family that recruits histone deacetylases to repress transcription. The gene is 
expressed in spinal nerves and boundary cap cells until about embryonic day E17, 
when Schwann cell precursors become immature Schwann cells (Leimeister et al., 
1999; Coulpier et al., 2009). In our analysis, Hey2 is expressed at low levels in adult 
nerves, and not activated during injury-induced Schwann cell de-differentiation (Fig 
7d and data not shown).  We therefore found Hey2 amongst the numerically most up-
regulated mRNAs in sciatic nerves of DhhCre::Sip1fl/fl mice at age P25. Moreover, 
Hey2 was strongly expressed in adult mutants 8 weeks after nerve injury. In both 
cases, "ectopic induction" of Hey2 was a special feature of Sip1-deficient Schwann 
cells. The physiological function of Hey2 in the Schwann cell lineage remains 
unknown. Conditional Dhh-Cre::Hey2flox/flox single mutants that we created in the 
course of our "rescue" experiments were normally developed and myelinated (data 
not shown). 
 
In promoter-reporter cotransfection assays with a luciferase readout, Sip1 repressed 
transcription of the Ednrb, Sox2 and Hey2 promoters in a Schwann cell line. This 
identified all three inhibitory genes also as direct Sip1 targets. 
 
One cannot assume that the phenotype of Sip1 mutant mice can be "rescued" by 
introducing a second mutation into one gene for a (de-repressed) inhibitor. It is thus 
surprising that the additional deletion of either Ednrb or Hey2 was sufficient to 
markedly increase the number of Krox20-positive Schwann cells and morphological 
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signs of sorting (more bundles with only 1-5 axons) in corresponding double-mutant 
mice. Experiments to find out whether these effects can be strengthened by targeting 
yet other genes and combining them in triple and quadruple mutants are important 
but beyond the scope of this first report.    
 
With the lack of radial sorting, conditional Sip1 mutants resemble mutants that lack 
normal basal lamina, such as beta 1 integrin and dystroglycan (Berti et al., 2011) or 
laminin 2 and 8 mutants (Yang, 2005). The basal lamina as a signalling platform 
between Schwann cell and the extracellular matrix is crucial for myelination as the 
analysis of numerous mouse mutant has shown (Feltri et al., 2008; Colognato and 
Tzvetanova, 2011). In conditional Sip1 mutants, the basal lamina is thin, diffuse and 
often discontinuous. DRG/Schwann cell cocultures from Sip1-deficient mice on either 
collagen or artificial basal lamina did not result in myelination (not shown), suggesting 
that the abnormal basal lamina is not by itself the cause of dysmyelination, but rather 
a secondary effect. 
 
In the CNS, myelination by oligodendrocytes is controlled in many ways by negative 
regulators. Direct interactions with signaling molecules, such as bone morphogenetic 
protein (BMP), Notch ligand, or Wnt proteins, can inhibit gene expression (Emery, 
2010). At the molecular level, chromatin remodelling and epigenetic silencing of 
transcriptional repressors also follows the principle "inhibiting the inhibitors" (Li et al., 
2009) . In oligodendrocyte development, Sip1 is also expressed, activated by Olig1 
and Olig2, and essential for CNS myelination, as illustrated in Olig-Cre::Sip1flox/flox 
mice (Weng et al., 2012). Surprisingly, in oligodendrocytes Sip1 serves a dual role as 
a transcriptional activator of the Smad7 gene and it is the lack of this protein, which 
contributes to CNS dysmyelination in conditional mutant mice (Weng et al., 2012). In 
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our analysis, Smad7 was not expressed or dysregulated in PNS development of Sip1 
mutant mice (data not shown). Thus, despite some phenotypical resemblence, Sip1 
serves different functions in PNS and CNS glial development.  
 
 
When we deleted Sip1 in Schwann cells of adult mice we found a severe delay in the 
regeneration and functional recovery after sciatic nerve crush injury. Even after eight 
weeks remyelination was not complete.  Such a dramatic failure of myelin repair has 
only been described in mice lacking the AP1 transcription factor c-Jun in Schwann 
cells (Arthur-Farraj et al., 2012). However, in c-Jun mutant mice, already the 
formation of repair cells is perturbed, which are properly generated in the conditional 
Sip1 mutants.  Thus, the inability of Sip1 mutant Schwann cells to redifferentiate and 
to remyelinate marks a distinct developmental defect.  
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Figure legends 
 
 
Figure 1. SIP1 expression in Schwann cell development and after injury. (a) 
Immunohistochemistry on sciatic nerve cross sections of wild type mice showing 
SIP1 expression at different developmental stages (red arrow heads, inset highlights 
one single SIP1-positive Schwann cell nucleus). SIP1 protein was virtually absent 
from Schwann cells of DhhCre::Sip1fl/fl mice at age E18.5 (inset highlights one single 
SIP1-negative Schwann cell nucleus). (b) SIP1 reexpression by mature Schwann 
cells at different time points after nerve crush (hpc: hours post crush, dpc: days post 
crush, ctrl: contralateral unharmed nerve) in distal stumps of injured sciatic nerves. 
(in (a) and (b): SIP1 brown, haematoxylin/nuclei blue, scale 10 µm, representative 
pictures of n=3 animals per time point and genotype except for the 14dpc time point 
n=4 and the contralateral nerve  n=7, bars represent mean values +/- SD). (c) 
Representative traces of electrophysiological measurements after sciatic nerve 
stimulation from DhhCre::Sip1fl/wt and DhhCre::Sip1fl/fl mice at age P25. (d) 
Quantification of SIP1-positive nuclei shown in (b). (e)-(g) Immunohistochemistry on 
sciatic nerves cross sections of DhhCre::Sip1fl/fl mice and controls detecting KROX20 
S100β and SOX2 (representative pictures of n=3 animals per genotype, KROX20, 
S100β and SOX2 are depicted in red, class III beta-tubulin (TuJ1) in green and DAPI 
in blue, scale 5 µm). 
 
Figure 2. Mice lacking Sip1 in Schwann cells develop a severe neuropathy. 
Nerves of DhhCre::Sip1fl/fl mice (b) appeared translucent compared to controls (a) 
and did not show any myelin basic protein at age P25 (MBP) staining ((d), control in 
(c), MBP green, axons are stained in red by a class III beta-tubulin (TuJ1) antibody, 
representative images of n=3 animals per genotype). Axons in control nerves had 
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been sorted and fully myelinated (e), while mutant nerves displayed large axon 
Schwann cell families and did not show any myelin (f). (g) Sip1-deficient Schwann 
cell engulfing two axons and displaying supernumerary loops of basal lamina (red 
arrow heads). (h) More than 50 axons surrounded by a single Schwann cell in the 
nerve of a conditional Sip1 mutant  (Schwann cell cytoplasm false-coloured in green). 
(i) Axons belonging to one bundle varied in size as illustrated by false colours (small 
axons: yellow, medium sized axon: red, large axon: purple). (j-m) Dysmyelination and 
large axon-Schwann cell families persisted to the age of one year (P365) in nerves of 
conditional mutants ((j) control, (k) and (m) mutant). One bundle of axons from a 
nerve of a conditional mutant at age P365 is depicted in (m). (Schwann cell 
cytoplasm false coloured in green, all images shown in g-m are representative of at 
least 3 animals per genotype and time point. Scale bars in all images 5 µm. 
 
Figure 3. Sip1-deficient Schwann cells continuously express maturation 
inhibitors. (a) Heat map of a microarray analysis depicting the 20 most up- and 
downregulated genes in sciatic nerves of 3 DhhCre::Sip1fl/fl mice (mut) compared to 
those of 3 control littermates (ctrl) at age P25 (red: high expression, blue: low 
expression). A subset of promyelinating factors and maturation inhibitors were 
confirmed by quantitative realtime PCR ((b): upregulated genes; (c): downregulated 
genes, n=6 animals per genotype, bars depict mean values +/- SD, note the 
logarithmic scale). (d) Luciferase assays showing Sip1-dose-dependent diminished 
luciferase activity of Hey2, Ednrb and Sox2 promoter constructs upon cotransfection 
with a Sip1 expression plasmid (bars represent mean values of 3 independent 
experiments +/- SEM, activity of lysates from S16 cells co-transfected with the pGL2-
luc plasmid containing the respective promoter fragment and the empty pCMV5 
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plasmid was considered 100%). (e) Scheme depicting the promoter fragments with 
predicted SIP1 binding sites used in (d). 
 
Figure 4. Sip1-mediated repression of Ednrb and Hey2 is functionally relevant 
in Schwann cells. (a) A subpopulation of Schwann cells in both Ednrb/Sip1 and 
Hey2/Sip1 conditional double mutants are KROX20-positive, while only few cells in 
Sip1 conditional mutants display a KROX20 signal (KROX20: red, class III beta- 
tubulin (TuJ1): green, DAPI: blue, representative images of n=5 animals per 
genotype, scale 5 µm). (b) Quantification of KROX20-positive nuclei (data are 
presented as mean values +/- SEM, n=5 animals per genotype, except Sip1fl/fl n=3 
animals, Sip1fl/fl vs. DhhCre::Sip1fl/fl P=0.008, DhhCre::Sip1fl/fl vs. 
DhhCre::Sip1fl/fl::Ednrbfl/fl P=0.03, DhhCre::Sip1fl/fl vs. DhhCre::Sip1fl/fl::Hey2fl/fl 
P=0.019, Sip1fl/fl vs. DhhCre::Sip1fl/fl::Hey2fl/fl P=0.004, Sip1fl/fl vs. 
DhhCre::Sip1fl/fl::Ednrbfl/fl P=0.018, two-sided student’s t-test of unpaired samples). 
(c) Improved radial sorting and smaller axon Schwann cell families in conditional 
double (DhhCre::Sip1fl/fl::Ednrbfl/fl or DhhCre::Sip1fl/fl::Hey2fl/fl) compared to single 
(DhhCre::Sip1fl/fl) mutants (representative images of 5 animals per genotype, scale 
10 µm) at age P25. (d) Significantly higher number of axon-Schwann cell units with 1 
to 5 axons per Schwann cell in both double mutant mice at age P25 compared to 
Sip1 single mutants (n=5 animals per genotype, at least 22 randomly chosen axon 
Schwann cell families per animal, mean values +/-SEM, DhhCre::Sip1fl/fl vs. 
DhhCre::Sip1fl/fl::Ednrbfl/fl  P=0.046, DhhCre::Sip1fl/fl vs. DhhCre::Sip1fl/fl::Hey2fl/fl 
P=0.02, two-sided student’s t-test of unpaired samples). 
 
Figure 5. Sip1 is crucial for functional recovery after injury. (a) Functional 
recovery of tamoxifen-treated PLPCreERT2::Sip1fl/fl mice (Cre+ fl/fl tamoxifen) was 
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significantly slower as determined by the sciatic functional index (SFI) compared to 3 
control groups. (n=10 animals per group and time point, mean values +/- SD are 
shown). (b)-(d) Electrophysiological recordings after sciatic nerve stimulation 52 days 
after crush revealed a conduction block in tamoxifen-treated PLPCreERT2::Sip1fl/fl 
mice while control nerves had regained roughly 70% of the nerve conduction velocity 
of the contralateral unharmed nerve ((b) representative traces, (c) quantification of 
nerve conduction velocity, (d) distal amplitude, bars represent mean values +/- SD, 
n=8 animals Sip1fl/fl tamoxifen-treated, n=5 animals PLPCreERT2::Sip1fl/fl tamoxifen-
treated). 
 
Figure 6. Remyelination by Sip1-deficient Schwann cells is impaired. (a) 
Immunohistochemistry for class III beta-tubulin (TuJ1, red) and MBP (green) on wax 
sections of sciatic nerves 56 days after crush showing large amyelinated fibers in 
tamoxifen-treated PLPCreERT2::Sip1fl/fl mice (Cre+ fl/fl tamox, representative images 
of 3 animals per group). (b) Ongoing remyelination in nerves of tamoxifen-treated 
PLPCreERT2::Sip1fl/fl mice 56 days after nerve crush evident by few non-compact 
myelin wraps as well as thin compact sheaths (scale 5 µm, boxed areas magnified in 
right panel). (c) Conditional mutants display fibrosis and large unmyelinated axons 56 
days after crush (bottom right panel, red arrow heads, scale 5 µm). (d) Significantly 
fewer remyelinated fibers in nerves of tamoxifen-treated PLPCreERT2::Sip1fl/fl mice 
28 and 56 days after nerve crush (dpc, upper panel, bars represent mean values +/- 
SD,  Sip1fl/fl tamoxifen-treated n=3, PLPCreERT2::Sip1fl/fl tamoxifen-treated n=4, 28 
days P=0.023, 56 days P=0.0078; lower panel, bars represent mean values +/- SD, 
Sip1fl/fl tamoxifen-treated n=3, PLPCreERT2::Sip1fl/fl tamoxifen-treated n=4, 
myelinated P=0.036, amyelinated P=0.027, two-tailed student’s t-test of unpaired 
samples). 
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Figure 7. Impaired redifferentiation of Sip1-deficient Schwann cells. (a) and (b) 
Unaltered number of remaining myelin profiles in tamoxifen-treated 
PLPCreERT2:Sip1fl/fl mice (red arrow heads, right panel) compared to controls (red 
arrow heads, left panel) shown by silver impregnation of the distal sciatic nerve 
stump 3 days after transection (scale in (a) 10 µm, n=3 mice per group, bars in (b) 
represent mean values +/- SD, student’s t-test for unpaired samples, P=0.50). (c) 
Comparable steady-state levels of mRNAs for c-jun and Sox2 in distal stumps of 
sciatic nerves of PLPCreERT2::Sip1fl/fl mice and controls 3 days after transection. 
Krox20 and Mpz mRNAs were similarily downregulated in both groups (n=3 mice per 
group, expression in the contralateral unharmed nerve was set to 1, bars represent 
mean values +/- SD). (d) Increased levels of Sox2, Id2 and Hey2 mRNAs in 
tamoxifen-treated PLPCreERT2::Sip1fl/fl mice 56 days after nerve crush compared to 
controls. Krox20 levels remained low in nerves of mutants (bars represent mean 
values +/- SD, n=6 mice Cre+ fl/fl tamoxifen, n=5 mice fl/fl tamoxifen, n=5 mice 
contralateral). (e) Delayed early axon regrowth in tamoxifen-treated 
PLPCreERT2::Sip1fl/fl mice compared to controls 4 days after nerve crush as 
assessed by the pinch test (bars depict mean values +/- SD, n=13 mice per group 
except for fl/fl tamoxifen n=16, fl/fl Cre+ tamoxifen versus fl/fl Cre+ vehicle P=0.006, 
fl/fl Cre+ tamoxifen versus fl/fl tamoxifen P=0.0011, fl/fl Cre+ tamoxifen versus fl/fl 
vehicle P=0.0027, student’s t-test of unpaired samples).   
 
Figure 8. Hypothetical working model of Sip1 function in Schwann cells 
(adapted from Jessen and Mirsky, 2005). The development of immature Schwann 
cells (imSC, immature basal lamina depicted in orange) to mature myelinating 
Schwann cells (myelSC, mature basal lamina yellow) is driven by positive 
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transcriptional regulators (green arrow). In parallel, suppressors of maturation (red 
arrow) need to be silenced. This is achieved by SIP1 acting as an “inhibitor of 
inhibition” thereby promoting differentiation. Sip1-inactivation in the Schwann cell 
lineage (Sip1-deficient SC, altered basal lamina light orange) leads to continous 
expression of differentiation inhibitors, such as Sox2, c-jun and Ednrb, and aberrant 
expression of the transcriptional repressor Hey2. At the same time, mRNA levels of 
Oct6, Krox20 and the genes coding for myelin proteins are low compared to mature 
myelinating Schwann cells. After injury, c-jun drives generation of an active repair 
cell, while Sip1 is crucial for the redifferentiation to a remyelination-competent 
Schwann cell. 
 
Supplementary Figure 1. Sip1-deficient Schwann cells survive and exit the cell 
cycle normally. (a) Unaltered levels of Schwann cell proliferation as detected by 
incorporation of Bromo-desoxyuridine (BrdU) in DhhCre::Sip1fl/fl mice compared to 
controls at E18.5, P10 and P25. Values are expressed as the percentage of BrdU-
positive cells of all DAPI-positive nuclei +/- SD. (b) The number of Schwann cell 
nuclei per cross section of sciatic nerve was unaltered between conditional single 
mutants (DhhCre::Sip1fl/fl) and both double conditional strains 
(DhhCre::Sip1fl/fl::Ednrbfl/fl and DhhCre::Sip1fl/fl::Hey2fl/fl) at age P25. Additionally, the 
Schwann cell number of DhhCre::Sip1fl/fl mice at age P365 was unaltered compared 
to P25 (n=3 animals per age and genotype, all bars depict mean values +/- SD). 
 
Supplementary Figure 2. Confirmation of recombination 4 weeks after the last 
tamoxifen-injection. 4 weeks after the last injection, endogenous tdTomato 
fluorescence (red) was observed in sciatic nerve cross sections of tamoxifen-treated 
PLPCreERT2::Sip1fl/fl mice (top panel), but not in treated Sip1fl/fl mice (bottom panel, 
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myelin/fluoromyelin in green, scale 10 µm, representative images from n=3 mice per 
genoytpe). 
 
Supplementary Figure 3. Inactivation of Sip1 in adult mice. Myelin sheath 
thickness was unaltered 12 weeks after the last injection in tamoxifen-treated 
PLPCreERT2::Sip1fl/fl mice compared to the 3 respective control groups. 
Representative images are shown in (a), a scatter plot depicting the gratio in relation 
to the fiber diameter for tamoxifen-treated PLPCreERT2::Sip1fl/fl mice compared to 
tamoxifen-terated Sip1fl/fl mice in (b), (n=3 animals per group, at least 100 randomly 
chosen fibers per animal, scale in (a) 5 µm). 
 
Supplementary Figure 4. Unaltered myelin sheath thickness after 
remyelination. Scatter plot depicting the gratio in relation to the fiber diameter of 
remyelinated fibers 8 weeks after nerve crush. No significant difference in myelin 
sheath thickness was observed between tamoxifen-treated PLPCreERT2::Sip1fl/fl 
mice and the 3 respective control groups (n=3 animals per group, at least 100 
randomly chosen fibers per animal).  
 
Supplementary Video 1 DhhCre::Sip1fl/fl mouse walking on a grid showing atactic 
movements and hind limb weakness. ! !
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Materials and Methods 
 
Mutant and transgenic mice 
All experiments involving mice were conducted according to the Lower Saxony State 
regulations for the use of experimental animals in Germany as approved by the 
Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit 
(LAVES) and performed in compliance with the animal policies of the Max Planck 
Institute of Experimental Medicine. Mice were housed in individually vented cages 
with a 12 hour light/dark cycle. Male and female mice were included in all 
experiments and randomly assigned to experimental groups according to age and 
genotype. Sip1fl/fl mice 22 were bred to DhhCre transgenic mice 23. 
DhhCre::Sip1fl/fl::Ednrbfl/fl mice were generated by breeding DhhCre::Sip1fl/wt::Ednrbfl/fl 
mice to Sip1fl/fl::Ednrbfl/fl mice 27. Floxed Hey2 mice (Xin et al., 2007) were acquired 
from Jackson laboratories. DhhCre::Sip1fl/fl::Hey2fl/fl mice were generated by breeding 
DhhCre::Sip1fl/wt::Hey2fl/fl mice to Sip1fl/fl::Hey2fl/fl mice. Floxed (double floxed) 
littermates were used as experimental controls in all experiments unless indicated 
otherwise. PLPCreERT2::Sip1fl/fl mice were generated by breeding Sip1fl/fl mice to 
PLPCreERT2 mice 29. Sip1 floxed mice, Hey2 floxed mice, PLPCreERT2 mice, and 
DhhCre mice were on C57/Black6 background, Ednrb floxed mice were on mixed 
C57Bl/6-SV129 background. Genotyping was performed on DNA isolated from tail or 
ear biopsies according to routine PCR methods using the following primers:  
DhhCre sense 5'-CCTGCGGAGATGCCCAATTG-3' antisense!!!!5'-CAGCCCGGAC 
CGACGATGAA-3' Sip1 floxed sense 5'-TGGACAGGAACTTGCATATGCT-3' anti- 
sense 5'-GTGGACTCTACATTCTAGATGC-3' Hey2 floxed sense 5'-CTAGAGAGG 
ACCTGGAGAGTTTAAG-3' antisense 5'-CTGTGCCACCAGCCTTAAAACC-3' Ednrb 
wild type allele sense 5'-CTGAGGAGAGCCTGATTGTGCCAC-3' antisense 5'-CGAC 
TCCAAGAAGCAACAGCTCG -3' Ednrb floxed allele sense 5'-TGGAATGTGTGCGA 
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GGCC -3' Ednrb floxed allele antisense 5'-CAGCCAGAACCACAGAGACCACCC -3' 
PLPCreERT2 transgene sense 5'-TGGACAGCTGGGACAAAGTAAGC -3'!antisense        
5'-CGTTGCATCGACCGGTAATGCAGGC -3'. 
 
Statistics 
Values are expressed as mean value +/- standard deviation (SD) unless indicated 
otherwise. Statistics were performed using the two-tailed Student’s t-test for unpaired 
samples assuming unequal variance and P values below 0,05 were considered 
significant (* <0,05; ** <0,01; *** <0,001). Normal distribution of data was assumed, 
but not formally tested.  
 
Induction of recombination, surgical procedures and foot print analysis 
PLPCreERT2::Sipfl/fl mice and Sip1flox/flox mice were treated twice for 5 consecutive 
days with one daily intraperitoneal injection of 1 mg tamoxifen in corn oil with 10% 
analytical ethanol (all from Sigma) or the corn oil/ethanol mixture only (vehicle). 
Sciatic nerve crush or transection was performed under deep surgical anaesthesia 
(ketaminhydrochloride 100 mg/kg and xylazinhydrochloride 5 mg/kg) at the sciatic 
notch. For crush injuries, the nerve was compressed for 15 seconds with fine 
forceps. To test early axon outgrowth (“pinch test”), mice were deeply anaesthetized 
4 days after crush injury, the sciatic nerve was completely exposed and pinched with 
fine forceps starting from the distal end until a muscle reaction was observed. The 
observer was blinded regarding genotype and treatment of the mice and the 
regeneration distance (distance from the crush site to the pinch site where a reaction 
was observed) was measured with a ruler in situ. Footprints were acquired during the 
light phase by painting the hind feet of mice with black colour and letting them run 
along a 50 cm walking track. Prints were digitalized and the distance between toe 1 
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and 5 and the length of the print measured using the FOOTPRINTS program 31. The 
sciatic functional index was calculated according to 32. The observer was blinded 
regarding the genotype of the mice. 
 
Electrophysiological measurements  
Electrophysiological measurements were performed under deep surgical anaesthesia 
(ketaminhydrochloride 100 mg/kg and xylazinhydrochloride 5 mg/kg). Two recording 
electrodes were inserted into the intrinsic foot muscle, distal stimulation electrodes 
were inserted at the ankle, and proximal stimulation electrodes were inserted at the 
sciatic notch. Compound muscle action potentials (CMAPs) were recorded with a 
Jaeger-Toennies Neuroscreen instrument. Nerve conduction velocities were 
calculated from the distance between proximal and distal stimulation electrodes 
(measured in situ) and the latency difference between the CMAPs after successive 
proximal and distal stimulation. CMAP amplitudes were calculated peak to peak. 
 
Morphology, silver impregnation and electron microscopy 
For ultrastructural analysis, nerves were immersion fixed in 2.5% glutardialdehyde 
and 4% paraformaldehyde in phosphate buffer and embedded into epoxy resin 
(Serva). Semithin sections were cut at a thickness of 0,5 µm (Leica RM 2155 using a 
diamond knife Histo HI 4317, Diatome) and stained with a mixture of 1% toluidine 
blue and 1% azur II or silver impregnated (Gallyas, 1979). Ultrathin sections were cut 
at a thickness of 50 nm, treated with uranyl acetate and lead citrate and analysed 
with a Zeiss EM 900 (Leo). The gratio was defined as the numerical ratio between 
the fiber diameter and the diameter of the same fiber including its myelin sheath and 
measured on electron micrographs for at least 100 randomly chosen axons per 
animal and nerve (3 animals per genotype and/or treatment group). Remyelinated 
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fibers after sciatic nerve crush were counted on complete semithin cross sections of 
sciatic nerves (n=3 animals per genotype and/or treatment group). The percentage of 
myelinated and unmyelinated axons 56 days after nerve crush was quantified by 
counting all fibers on 25 randomly taken electron micrographs at 3000x magnification 
per animal (n=3 animals per genotype and treatment group).  Axons per bundle were 
quantified on electron microscopic images by analysing all axon Schwann cell units 
where the nucleus of the Schwann cell was visible (amounting to at least 22 
randomly chosen axon-Schwann cell units per animal and nerve, 3 animals per 
genotype). For gratio analysis, quantification of remyelinated fibers and quantification 
of axons per Schwann cell, the observer was blinded regarding the genotype and/or 
treatment (tamoxifen or vehicle) of the animals. 
 
Immunohistochemistry  
Samples were immersion fixed using 4% phosphate buffered paraformaldehyde and 
embedded into paraffin wax. Immunohistochemistry was performed on 5 µm thick 
sections using the LSAB2 system (DAKO) or secondary antibodies coupled to a 
fluorophore (Alexa555 or -488 donkey anti mouse, all from Molecular Probes diluted 
1:2000). For heat-induced antigen retrieval, slides were boiled for 20 minutes in 
citrate buffer pH 6. The following primary antibodies were used: Sip1 (SC27-1984, 
Santa Cruz: 1:200), betaIII-tubulin (MMS-435P, Covance 1:250), MBP (A0623, 
DAKO 1:500), Krox20 (rabbit, generous gift of Dies Meijer 1:500), Sox2 (SC1002, 
Millipore 1:200), S100β (AB52642, Abcam, 1:500). For each staining, samples from 
at least 3 individual animals per genotype (or treatment group) were processed 
simultaneously and used for the analysis. Sections were examined with a Zeiss 
Observer fluorescence microscope or Zeiss Axiophot brightfield microscope and 
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images acquired with Openlab 3.1.1 software (Improvision). Images were processed 
with Adobe Photoshop 12.0.4, Adobe Illustrator CS5 and NIH Image J 1.46R. 
 
RNA preparation, cDNA synthesis, realtime PCR and microarray analysis 
RNA was isolated from sciatic nerves using the RNeasy Kit (Qiagen) according to 
manufacturer’s instructions and the concentration and quality (ratio of absorption at 
260/280 nm) evaluated using the NanoDrop spectrophotometer. Reverse 
transcription was performed with 1 µg of total RNA using the Superscript Kit 
(Invitrogen) and random nonamer primers. Quantitative realtime PCR was performed 
in triplicate for each sample using SybrGreen (Life Technologies) and the ABI PRISM 
7700 detection system (Perkin Elmer). Four mice per genotype and/or treatment 
group were used in each experiment unless specified otherwise, relative mRNA 
concentrations were determined using the threshold cycle method and normalized to 
Rpl8. Primer pairs: Sox2 sense 5'-TCCAAAAACTAATCACAACAATCG-
3' antisense 5'-GAAGTGCAATTGGGATGAAAA-3' Id2 sense 5'-
GACAGAACCAGGCGTCCA-3' antisense 5'-AGCTC 
AGAAGGGAATTCAGATG-3' Oct6 sense 5'-AGCACTCGGACGAGGATG-3' antisen- 
se 5'-TTGAACTGCTTGGCGAACT-3' p75NTR sense 5'-CGGTGTGCGAGGACACT 
GAGC-3' antisense 5'-TGGGTGCTGGGTGTTGTGACG-3' c-jun sense 5'-CTGAGTG 
TGCGAGAGACAGC-3 antisense 5'-CCAAGTCCGTCCGTCTGT-3' Krox20 sense 5'-
AATGGCTTGGGACTGACTTG-3' antisense 5'-GCCAGAGAAACCTCCATTCA-3' 
MPZ sense 5'-ACTTGGCCTTCCCATCTCTC-3' MPZ antisense 5'-GGGCCACCAG 
AAGGTAGG-3' Sip1 sense 5'-CAAGAGGCGCAAACAAGC-3' antisense 5'-TGCGTC 
CACTACGTTGTCAT-3' Hey2 sense 5'-ATTGCAAATGACAGTGGATCAT-3' antisen- 
Se 5'-AGCATGGGCATCAAAGTAGC-3' Rpl8 sense 5'-CAACAGCGCCGTTGTTGG 
T-3 antisense 5'-CAGCCTTTAAGATAGGCTTGTCA-3'.  
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P values for quantitative realtime PCR experiments are as follows: Figure 3b: Gfap 
0.026, Hey2 P=4.57E-05, Ednrb P=0.002, Sox2 P=1.4E-05, Brn2 P=0.0006, Id2 
P=0.0004, c-jun P=0.008, N-cad P=8.18E-06; figure 3c: Pmp2 P=3.5E-05, Mpz 
P=0.0001, Cnp1 P=9.56E-05, Krox20 P=0.002, Oct6 P=0.001, S100β P=0.002, 
p75Ntfr P=0.005, Erb3 P=0.0003, E-cad P=0.0006, Itga4 P=0.0003. Figure 7c: c-jun: 
fl/fl vehicle vs. fl/fl tamoxifen P=0.236, fl/fl vehicle vs. Cre+ fl/fl tamoxifen P=0.99, fl/fl 
vehicle vs. Cre+ fl/fl vehicle P=0.065, fl/fl tamoxifen vs. Cre+ fl/fl tamoxifen P=0.692; 
Cre+ fl/fl vehicle vs. Cre+ fl/fl tamoxifen P=0.263, Cre+ fl/fl vehicle vs. fl/fl tamoxifen 
P=0.14; Sox2: fl/fl vehicle vs. fl/fl tamoxifen P=0.144, fl/fl vehicle vs. Cre+ fl/fl 
tamoxifen P=0.53, fl/fl vehicle vs. Cre+ fl/fl vehicle P=0.476, fl/fl tamoxifen vs. Cre+ 
fl/fl tamoxifen P=0.386; Cre+ fl/fl vehicle vs. Cre+ fl/fl tamoxifen P=0.256, Cre+ fl/fl 
vehicle vs. fl/fl tamoxifen P=0.07; Krox20: fl/fl vehicle vs. fl/fl tamoxifen P=0.344, fl/fl 
vehicle vs. Cre+ fl/fl tamoxifen P=0.215, fl/fl vehicle vs. Cre+ fl/fl vehicle P=0.027, fl/fl 
tamoxifen vs. Cre+ fl/fl tamoxifen P=0.471; Cre+ fl/fl vehicle vs. Cre+ fl/fl tamoxifen 
P=0.083, Cre+ fl/fl vehicle vs. fl/fl tamoxifen P=0.067; Mpz: fl/fl vehicle vs. fl/fl 
tamoxifen P=0.449, fl/fl vehicle vs. Cre+ fl/fl tamoxifen P=0.391, fl/fl vehicle vs. Cre+ 
fl/fl vehicle P=0.216, fl/fl tamoxifen vs. Cre+ fl/fl tamoxifen P=0.184; Cre+ fl/fl vehicle 
vs. Cre+ fl/fl tamoxifen P=0.369, Cre+ fl/fl vehicle vs. fl/fl tamoxifen P=0.135; Figure 
7d: Sox2: contralateral (ctrl) vs. fl/fl tamoxifen P=0.001, ctrl vs. Cre+ fl/fl tamoxifen 
P=0.001, fl/fl tamoxifen vs. Cre+ fl/fl tamoxifen P=0.007; Id2: ctrl vs. fl/fl tamoxifen 
P=0.0004, ctrl vs. Cre+ fl/fl tamoxifen P=3.003E-05, fl/fl tamoxifen vs. Cre+ fl/fl 
tamoxifen P=0.01; Hey2: ctrl vs. fl/fl tamoxifen P=0.0003, ctrl vs. Cre+ fl/fl tamoxifen 
P=0.0003, fl/fl tamoxifen vs. Cre+ fl/fl tamoxifen P=0.0001; Krox20 ctrl vs. fl/fl 
tamoxifen P=0.69, ctrl vs. Cre+ fl/fl tamoxifen P=0.0014, fl/fl tamoxifen vs. Cre+ fl/fl 
tamoxifen P=0.01). 
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Microarray analysis was performed at the Transcriptome Analysis Laboratory (TAL) 
of the University Göttingen using the Affymetrix GeneChip Mouse Gene 1.0 ST 
platform. 3 animals per genotype were compared and genes were considered to be 
regulated when changes were at least 2 fold up or down compared to controls. 
 
Luciferase reporter assay 
Promoter regions (mouse genome version mm10) for analysis of Sip1 binding were 
chosen using the eukaryotic promoter database (http://epd.vital-it.ch/). The Sox2 
promoter region (chromosome 3 between positions 34,648,778 - 34,650,029) is 
localized relative to the transcriptional start site of the Sox2 gene -1239bp to +51bp. 
The Hey2 promoter region (chromosome 10 between positions 30,842,764 - 
30,845,280) is localized relative to the transcriptional start site of the Hey2 gene -
2499bp to +18bp. The Ednrb promoter region (chromosome 14 between positions 
103,844,229 - 103,846,824) is localized relative to the transcriptional start site of the 
Ednrb gene (variant EdnRB_1) -2497bp to +99bp. Promoter regions were amplified 
by PCR and inserted as XhoI/XmaI fragments upstream of the luciferase gene into 
pGL2-luc (Promega). The following primers were used for the amplification of 
promoter regions: for Sox2 5´GCGCcccgggGGCAGGCAAGATTCTTGAAC 3´ and 5´
GCGCctcgagCTCTGCCTTGACAACTCCTG 3´, for Hey2 5´GCGCcccgggCTCTGAC
CCAGACGTAGGAC 3´ and 5´ GCGCctcgagCGGCTCCTGGAGGTTCTTTC 3´ and  
for EdnRB 5´GCGCcccgggGGTAGTTTAATGCGCCCATC 3´ and 5´GCGCctcgagGC
TGCTCCTAAACAGGCCTC 3´. 
For luciferase reporter gene assays, the S16 Schwann cell line was used. Cells were 
transfected using polyethylenimin (PEI) on 3.5 cm tissue culture plates with 1.5 µg of 
luciferase reporter (pGL2-luc) and varying amounts (0.3 µg, 0.9 µg or 1.5 µg) of 
pCMV5-Sip1expression vector. Cells were generally harvested 48 h post-transfection 
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and luciferase activity was determined in the presence of luciferin substrate by 
detection of chemiluminescence. Single values: Ednrb 0.3 µg Sip1 plasmid 91% +/- 
2.7, 0.9 µg 63% +/- 3.9, 1.5 µg 58% +/- 3.5, Sox2 0.3 µg Sip1 plasmid 85% +/- 5, 0.9 
µg 41% +/- 6.8, 1.5 µg 26% +/- 2.3, Hey2 0.3 µg Sip1 plasmid 93% +/- 11.4, 0.9 µg 
68% +/- 3.3, 1.5 µg 41% +/- 9.6). 
 
Supplementary Methods 
BrdU injections and immunohistochemistry 
Bromodesoxiuridine (BrdU) was solubilized in water at a concentration of 10 mg/ml. 
Mice at the age of 10 or 25 days were injected intraperitoneally with one pulse of 100 
µg/g body weight and sacrificed 4 hours later. Pregnant female mice at E18.5 were 
treated the same way and sacrificed 70 minutes after the pulse. Sciatic nerves were 
embedded into wax and cut at a thickness of 5 µm. For detection of BrdU-positive 
nuclei, sections were boiled for 5 minutes at 100W in a microwave in citrate buffer 
pH6, incubated for 30 minutes at room temperature in 0.2 M glycine followed by two 
washes in 100 mM disodium tetraborate pH 8.5. Anti-BrdU antibody (MAB3424, 
Millipore) was diluted 1:200 in 2% goat serum in PBS and applied over night at 4°C. 
After washing, the secondary antibody (Alexa555-anti-mouse, 1:2000, A-31570, 
Molecular Probes) and DAPI (0.05 µg/ml) were applied for 1 hour at room 
temperature. For quantification of proliferating cells, all BrdU/DAPI-positive nuclei 
were counted on cross sections of sciatic nerves and values expressed as 
percentage of BrdU-positive cells relative to all DAPI-positive nuclei. !! !
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Figure 1. SIP1 expression in Schwann cell development and after injury. (a) Immunohistochemistry 
on sciatic nerve cross sections of wild type mice showing SIP1 expression at different developmental 
stages (red arrow heads, inset highlights one single SIP1-positive Schwann cell nucleus). SIP1 protein 
was virtually absent from Schwann cells of DhhCre::Sip1fl/fl mice at age E18.5 (inset highlights one 
single SIP1-negative Schwann cell nucleus). (b) SIP1 reexpression by mature Schwann cells at different 
time points after nerve crush (hpc: hours post crush, dpc: days post crush, ctrl: contralateral unharmed 
nerve) in distal stumps of injured sciatic nerves. (in (a) and (b): SIP1 brown, haematoxylin/nuclei blue, 
scale 10 µm, representative pictures of n=3 animals per time point and genotype except for the 14dpc 
time point n=4 and the contralateral nerve  n=7, bars represent mean values +/- SD). (c) Representative 
traces of electrophysiological measurements after sciatic nerve stimulation from DhhCre::Sip1fl/wt and 
DhhCre::Sip1fl/fl mice at age P25. (d) Quantification of SIP1-positive nuclei shown in (b). (e)-(g) 
Immunohistochemistry on sciatic nerves cross sections of DhhCre::Sip1fl/fl mice and controls detecting 
KROX20 S100β and SOX2 (representative pictures of n=3 animals per genotype, KROX20, S100β and 
SOX2 are depicted in red, class III beta-tubulin (TuJ1) in green and DAPI in blue, scale 5 µm).
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Figure 2. Mice lacking Sip1 in Schwann cells develop a severe neuropathy. Nerves of 
DhhCre::Sip1fl/fl mice appeared translucent (b) compared to controls (a) and did not show any myelin 
basic protein (MBP) staining at age P25 ((d), control in (c), MBP green, axons are stained in red by a 
class III beta-tubulin (TuJ1) antibody, representative images of n=3 animals per genotype). Axons in 
control nerves had been sorted and fully myelinated (e), while mutant nerves displayed large axon 
Schwann cell families and did not show any myelin ((f), representative images of n=5 animals per 
genotype). (g) Sip1-deficient Schwann cell engulfing two axons and displaying supernumerary loops of 
basal lamina (red arrow heads). (h) More than 50 axons surrounded by a single Schwann cell in the 
nerve of a conditional Sip1 mutant  (Schwann cell cytoplasm false-coloured in green). (i) Axons 
belonging to one bundle varied in size as illustrated by false colours (small axons: yellow, medium sized 
axon: red, large axon: purple). (j-m) Dysmyelination and large axon-Schwann cell families persisted to 
the age of one year (P365) in nerves of conditional mutants ((j) control, (k) and (m) mutant). One bundle 
of axons from a nerve of a conditional mutant at age P365 is depicted in (m, Schwann cell cytoplasm 
false coloured in green). All images shown in g-m are representative of at least 3 animals per genotype 
and time point. Scale bars in all images 5 µm.
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Figure 3. Sip1-deficient Schwann cells continuously express maturation inhibitors. (a) Heat map 
of a microarray analysis depicting the 20 most up- and downregulated genes in sciatic nerves of 3 
DhhCre::Sip1fl/fl mice (mut) compared to those of 3 control littermates (ctrl) at age P25 (red: high 
expression, blue: low expression). A subset of promyelinating factors and maturation inhibitors were 
confirmed by quantitative realtime PCR ((b): upregulated genes; (c): downregulated genes, n=6 animals 
per genotype, bars depict mean values +/- SD, note the logarithmic scale). (d) Luciferase assays 
showing Sip1-dose-dependent diminished luciferase activity of Hey2, Ednrb and Sox2 promoter 
constructs upon cotransfection with a Sip1 expression plasmid (bars represent mean values of 3 
independent experiments +/- SEM, activity of lysates from S16 cells co-transfected with the pGL2-luc 
plasmid containing the respective promoter fragment and the empty pCMV5 plasmid was considered 
100%). (e) Scheme depicting the promoter fragments with predicted SIP1 binding sites used in (d). 
Numbers indicate location on the respective mouse chromosome.
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Figure 4. Sip1-mediated repression of Ednrb and Hey2 is functionally relevant in Schwann cells. 
(a) A subpopulation of Schwann cells in both Ednrb/Sip1 and Hey2/Sip1 conditional double mutants are 
KROX20-positive, while only few cells in Sip1 conditional mutants display a KROX20 signal (KROX20: 
red, class III beta-tubulin (TuJ1): green, DAPI: blue, representative images of n=5 animals per genotype, 
scale 5 µm). (b) Quantification of KROX20-positive nuclei (data are presented as mean values +/- SEM, 
n=5 animals per genotype, except Sip1fl/fl n=3 animals, Sip1fl/fl vs. DhhCre::Sip1fl/fl P=0.008, 
DhhCre::Sip1fl/fl vs. DhhCre::Sip1fl/fl::Ednrbfl/fl P=0.03, DhhCre::Sip1fl/fl vs. DhhCre::Sip1fl/fl::Hey2fl/fl 
P=0.019, Sip1fl/fl vs. DhhCre::Sip1fl/fl::Hey2fl/fl P=0.004, Sip1fl/fl vs. DhhCre::Sip1fl/fl::Ednrbfl/fl P=0.018, 
two-sided student’s t-test of unpaired samples). (c) Improved radial sorting and smaller axon Schwann 
cell families in conditional double (DhhCre::Sip1fl/fl::Ednrbfl/fl or DhhCre::Sip1fl/fl::Hey2fl/fl) compared to 
single (DhhCre::Sip1fl/fl) mutants (representative images of 5 animals per genotype, scale 10 µm) at age 
P25. (d) Significantly higher number of axon-Schwann cell units with 1 to 5 axons per Schwann cell in 
both double mutant mice at age P25 compared to Sip1 single mutants (n=5 animals per genotype, at 
least 25 randomly chosen axon Schwann cell families per animal, mean values +/-SEM, DhhCre::Sip1fl/fl 
vs. DhhCre::Sip1fl/fl::Ednrbfl/fl  P=0.046, DhhCre::Sip1fl/fl vs. DhhCre::Sip1fl/fl::Hey2fl/fl P=0.02, two-sided 
student’s t-test of unpaired samples). 
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Figure 5. Sip1 is crucial for functional recovery after injury. (a) Functional recovery of 
tamoxifen-treated PLPCreERT2::Sip1fl/fl mice (Cre+ fl/fl tamoxifen) was significantly slower 
as determined by the sciatic functional index (SFI) compared to 3 control groups (n=10 
animals per group and time point, mean values +/- SD). (b)-(d) Electrophysiological 
recordings after sciatic nerve stimulation 52 days after crush revealed a conduction block 
in tamoxifen-treated PLPCreERT2::Sip1fl/fl mice while control nerves had regained roughly 
70% of the nerve conduction velocity of the contralateral unharmed nerve ((b) 
representative traces, (c) quantification of nerve conduction velocity, (d) distal amplitude, 
bars represent mean values +/- SD, n=8 animals Sip1fl/fl tamoxifen-treated, n=5 animals 
PLPCreERT2::Sip1fl/fl tamoxifen-treated). 
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Figure 6. Remyelination by Sip1-deficient Schwann cells is impaired. (a) 
Immunohistochemistry for class III beta-tubulin (TuJ1, red) and MBP (green) on wax sections of 
sciatic nerves 56 days after crush showing large amyelinated fibers in tamoxifen-treated 
PLPCreERT2::Sip1fl/fl mice (Cre+ fl/fl tamox, representative images of 3 animals per group). (b) 
Ongoing remyelination in nerves of tamoxifen-treated PLPCreERT2::Sip1fl/fl mice 56 days after 
nerve crush evident by few non-compact myelin wraps as well as thin compact sheaths (scale 5 
µm, boxed areas magnified in right panel). (c) Conditional mutants display fibrosis and large 
unmyelinated axons 56 days after crush (bottom right panel, red arrow heads, scale 5 µm). (d) 
There were significantly fewer remyelinated fibers in nerves of tamoxifen-treated 
PLPCreERT2::Sip1fl/fl mice 28 and 56 days after nerve crush (upper panel, bars represent mean 
values +/- SD,  Sip1fl/fl tamoxifen-treated n=3, PLPCreERT2::Sip1fl/fl tamoxifen-treated n=4, 28 
days P=0.023, 56 days P=0.0078, two-tailed student’s t-test of unpaired samples) and roughly 
11% of axons had remained amyelinated 56 days after crush (lower panel, bars represent mean 
values +/- SD, Sip1fl/fl tamoxifen-treated n=3, PLPCreERT2::Sip1fl/fl tamoxifen-treated n=4, 
myelinated P=0.036, amyelinated P=0.027, two-tailed student’s t-test of unpaired samples). 
!"
#!!"
$!!!"
$#!!"
%!!!"
%#!!"
&
'(
)*
+",
-"+
*(
./
0/
01
"(
2*
3/0
"4
+,
-/3
*5
"/0
"6
/5
7.
3"5
7'
(
4"
8+*9"-3:-3";*</=3*"
8+*9"-3:-3"7.(,>/-*0"
-3:-3";*</=3*"
-3:-3"7.(,>/-*0"
8+*9"-3:-3";*</=3*"
8+*9"-3:-3"7.(,>/-*0"
8+*9"-3:-3";*</=3* 8+*9"-3:-3"7.(,>/-*0
.
=
0?5?
@'/07*5A"B+/0C(.00"*7".3?A"D/1'+*"E
F"
#"
G"
E"
H"
I
*1
*0
*+
.7
/,
0"
3*
01
7<
/0
"7<
*"
4/
0=
<"
7*
57
"J(
(
K"
6
-3:-3";*</=3*"
-3:-3"7.(,>/-*0"
8+*9"-3:-3";*</=3*"
8+*9"-3:-3"7.(,>/-*0"
*
!"
$"
%"
L"
F"
#"
M,>%" N6%" O*2%"
=,07+.3.7*+.3"J5*7"7,$K"
-3:-3"7.(,>/-*0"
8+*9"-3:-3"7.(,>/-*0"
I
*3
.7
/;
*"
(
I
&
P"
*>
4+
*5
5/
,0
&,+(.3"6*6/--*+*07/.7/,0"L"6.25".-7*+"7+.05*=7/,0"/0"6/57.3"57'(4
D'0=7/,0.3"+*=,;*+2"
F"6.25".-7*+"=+'5<
!"
!AF"
!AH"
$A%"
  Q+,>%!"
*
**
*
***
***
***
*0?5?
I
*3
.7
/;
*"
(
I
&
P"
*>
4+
*5
5/
,0
I*6/--*+*07/.7/,0"#G"6.25".-7*+"=+'5<"/0"6/57.3"57'(4
=,07+.3.7*+.3"J5*7"7,"$K"
-3:-3"7.(,>/-*0"
8+*9"-3:-3"7.(,>/-*0"
!"
$"
%"
L"
F"
=RS'0" M,>%"
I
*3
.7
/;
*"
(
I
&
P"
*>
4+
*5
5/
,0
"
0?5?
0?5?
)
=,07+,35
0?5? **
!"
!A!F"
!A!H"
!A$%"
!A$G"
Q+,>%!" T4U"
0?5?
0?5?
I
*3
.7
/;
*"
(
I
&
P"
*>
4+
*5
5/
,0
"
*
!"#$%&'()'*+,-"%&.'%&."//&%&01"-1"20'2/'3",45.&/"6"&01'3678-00'6&99:)"J.K".06"J)K"V0.37*+*6"
0'()*+",-"+*(./0/01"(2*3/0"4+,-/3*5"/0"7.(,>/-*0R7+*.7*6"WXW8+*YIZ%[M/4$-3:-3"(/=*"J+*6".++,\"
<*.65A" +/1<7" 4.0*3K" =,(4.+*6" 7," =,07+,35" J+*6" .++,\" <*.65A" 3*-7" 4.0*3K" 5<,\0" )2" 5/3;*+"
/(4+*10.7/,0",-"7<*"6/57.3"5=/.7/="0*+;*"57'(4"L"6.25".-7*+"7+.05*=7/,0"J5=.3*"/0"J.K"$!"](A"0^L"
(/=*"4*+"1+,'4A").+5"/0"J)K"+*4+*5*07"(*.0";.3'*5"9:R"M_A"57'6*07`5"7R7*57"-,+"'04./+*6"5.(43*5A"
W^!?#!K?"J=K"8,(4.+.)3*"57*.62R57.7*" 3*;*35",-"(I&P5"-,+"=RS'0".06"M,>%"/0"6/57.3"57'(45",-"
5=/.7/="0*+;*5",-"WXW8+*YIZ%[[M/4$-3:-3"(/=*".06"=,07+,35"L"6.25".-7*+" 7+.05*=7/,0?"Q+,>%!".06"
T4U" (I&P5" \*+*" 6+.57/=.332" 6,\0+*1'3.7*6" /0" ('7.075" .06" 7<*" 6/--*+*07" =,07+,3" 1+,'45"
J*>4+*55/,0"/0"7<*"=,07+.3.7*+.3"'0<.+(*6"0*+;*"\.5"5*7"7,"$A").+5"+*4+*5*07"(*.0";.3'*5"9:R"
M_K?" J6K" N0=+*.5*6" 3*;*35" ,-" M,>%A" N6%" .06" O*2%" (I&P5" /0" 7.(,>/-*0R7+*.7*6"
WXW8+*YIZ%[[M/4$-3:-3" (/=*" #G" 6.25" .-7*+" 0*+;*" =+'5<" =,(4.+*6" 7," =,07+,35?" Q+,>%!" 3*;*35"
+*(./0*6" 3,\" /0" 0*+;*5" ,-"('7.075" J).+5" +*4+*5*07"(*.0" ;.3'*5" 9:R" M_A" 0^G"(/=*"8+*9" -3:-3"
7.(,>/-*0A"0^#"(/=*"-3:-3"7.(,>/-*0A"0^#"(/=*"=,07+.3.7*+.3K?"J*K"_*3.2*6"*.+32".>,0"+*1+,\7<"/0"
7.(,>/-*0R7+*.7*6"WXW8+*YIZ%[[M/4$-3:-3"(/=*"=,(4.+*6"7,"=,07+,35"F"6.25".-7*+"0*+;*"=+'5<".5"
.55*55*6")2"7<*"4/0=<"7*57"J).+5"6*4/=7"(*.0";.3'*5"9:R"M_A"0^$L"(/=*"4*+"1+,'4"*>=*47"-,+"-3:-3"
7.(,>/-*0" 0^$GA" -3:-3" 8+*9" 7.(,>/-*0" ;*+5'5" -3:-3" 8+*9" ;*</=3*" W^!?!!GA" -3:-3" 8+*9" 7.(,>/-*0"
;*+5'5"-3:-3"7.(,>/-*0"W^!?!!$$A"-3:-3"8+*9"7.(,>/-*0";*+5'5"-3:-3";*</=3*"W^!?!!%EA"57'6*07`5"7R7*57"
,-"'04./+*6"5.(43*5K?""
axon
Sox2 c-jun
Ednrb Hey2
Sip1-deficiency
axon
Sox2 c-jun
Sip1
Pax3
Krox20
Oct6
Brn2
Sox10
Nab1/2
Nf-țB
Yy1
imSC myelSC
Sip1-deficient SC
repair cell
c-jun
Sip1
Figure 8. Hypothetical working model of Sip1 function in Schwann cells (adapted from Jessen and 
Mirsky, 2005). The development of immature Schwann cells (imSC, immature basal lamina depicted in 
orange) to mature myelinating Schwann cells (myelSC, mature basal lamina yellow) is driven by positive 
transcriptional regulators (green arrow). In parallel, suppressors of maturation (red arrow) need to be 
silenced. This is achieved by SIP1 acting as an “inhibitor of inhibition” thereby promoting differentiation. 
Sip1-inactivation in the Schwann cell lineage (Sip1-deficient SC, altered basal lamina light orange) leads 
to continous expression of differentiation inhibitors, such as Sox2, c-jun and Ednrb, and aberrant 
expression of the transcriptional repressor Hey2. At the same time, mRNA levels of Oct6, Krox20 and 
the genes coding for myelin proteins are low compared to mature myelinating Schwann cells. After 
injury, c-jun drives generation of an active repair cell, while Sip1 is crucial for the redifferentiation to a 
remyelination-competent Schwann cell. 
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Supplementary Figure 1. Sip1-deficient Schwann cells survive and exit the cell cycle 
normally. (a) Unaltered levels of Schwann cell proliferation as detected by incorporation of 
Bromo-desoxyuridine (BrdU) in DhhCre::Sip1fl/fl mice compared to controls at E18.5, P10 and 
P25. Values are expressed as the percentage of BrdU-positive cells of all DAPI-positive nuclei 
+/- SD. (b) The number of Schwann cell nuclei per cross section of sciatic nerve was unaltered 
between conditional single mutants (DhhCre::Sip1fl/fl) and both double conditional strains 
(DhhCre::Sip1fl/fl::Ednrbfl/fl and DhhCre::Sip1fl/fl::Hey2fl/fl) at age P25. Additionally, the Schwann 
cell number of DhhCre::Sip1fl/fl mice at age P365 was unaltered compared to P25 (n=3 animals 
per age and genotype, all bars depict mean values +/- SD).
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Quintes, Brinkmann et al., Supplementary Figure 2
Supplementary Figure 2. Confirmation of recombination 4 weeks after the last 
tamoxifen-injection. 4 weeks after the last injection, endogenous tdTomato fluorescence (red) 
was observed in sciatic nerve cross sections of tamoxifen-treated PLPCreERT2::Sip1fl/fl mice 
(top panel), but not in treated Sip1fl/fl mice (bottom panel, myelin/fluoromyelin in green, scale 10 
µm, representative images from n=3 mice per genoytpe). 
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Quintes, Brinkmann et al., Supplementary Figure 3 
Supplementary Figure 3. Inactivation of Sip1 in adult mice. Myelin sheath thickness was 
unaltered 12 weeks after the last injection in tamoxifen-treated PLPCreERT2::Sip1fl/fl mice 
compared to the 3 respective control groups. Representative images are shown in (a), a scatter 
plot depicting the gratio in relation to the fiber diameter for tamoxifen-treated 
PLPCreERT2::Sip1fl/fl mice compared to tamoxifen-terated Sip1fl/fl mice in (b), (n=3 animals per 
group, at least 100 randomly chosen fibers per animal, scale in (a) 5 µm). 
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Supplementary Figure 4. Unaltered myelin sheath thickness after remyelination. Scatter 
plot depicting the gratio in relation to the fiber diameter of remyelinated fibers 8 weeks after 
nerve crush. No significant difference in myelin sheath thickness was observed between 
tamoxifen-treated PLPCreERT2::Sip1fl/fl mice and the 3 respective control groups (n=3 animals 
per group, at least 100 randomly chosen fibers per animal). 
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